Signaling Pathways in Squamous Cancer
Springer-Verlag New York Inc.
978-1-4419-7202-6 (ISBN)
We propose to organize the book so that the early chapters will focus on individual pathways and more specific mechanisms in both normal function and cancer, while the later chapters will be more integrative and include overviews of biomarkers and therapeutic development. This should increase interest for clinically oriented researchers. All authors will be encouraged to provide a balanced review in addition to highlighting their own work.
1. Regulation of Squamous Differentiation
p63
Dennis Roop
Wendy Weinberg, FDA
Notch
Raphael Kopan, Washington University School of Medicine St. Louis
Michael Parmacek, U. Penn
beta-catenin/wnts
Elaine Fuchs: Rockefeller
Fiona Watt Cambridge Research Institute , UK
Sarah Millar: U. Penn
AP1
Peter Angel, German Cancer Research Center
T.Bowden (UV and AP1) University of Arizona
Nuclear Hormone receptors
PPAR: Jeff Peters, Penn State
NF-kB: M. Karin, UCSD
2. Regulation of Proliferation and Survival
EGFR family
J. Grandis Pittsburgh
L. Hansen, Creighton University
Stats
J. DiGiovanni, MD Anderson
TGF
Michael Reiss
Elaine Fuchs Rockefeller
Adam Glick, Penn State
p53/p63/p73
3. Regulation of Inflammatory Signaling
Carter Van Waes, NCI
D. Hanahan, UCSF
Lisa Coussens, UCSF
4. Regulation of Migration, Invasion, Matrix and Basement Membrane Interactions and Metastasis
Integrin signaling
Arthur Mercurio: Harvard University
MET signaling in migration and angiogenesis
Zhong Chen and Gang Dong: NIDCD and NIAID
Matrix production and degradation
Eben Rosenthal, Univeristy of Alabama
Lynn Matrisian, Vanderbilt
5. Integration of aberrant signaling in transcriptional dysregulation of gene and protein expression in squamous cell carcinoma
Zhong Chen, Bin Yan and Carter Van Waes
6. Effects and therapeutic potential of targeting dysregulated signaling axes in squamous cell carcinoma
EGFR, SRC, STAT3: Jennifer Grandis and coauthors
NF-kappaB: Clint Allen, Liesl Nottingham and Carter Van Waes
P16, p53, p63: James Rocco and Leif Ellisen, Harvard
AKT and mTOR: Silvio Gutkind, NIDCR and Cherie-Ann O Nathan,
PPAR:Frank Ondrey and Eva Szabo, University Minnesota, NCI
Erscheint lt. Verlag | 25.11.2010 |
---|---|
Zusatzinfo | XX, 462 p. |
Verlagsort | New York, NY |
Sprache | englisch |
Maße | 155 x 235 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Studium | |
ISBN-10 | 1-4419-7202-1 / 1441972021 |
ISBN-13 | 978-1-4419-7202-6 / 9781441972026 |
Zustand | Neuware |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich